1. Home
  2. OTH vs SERA Comparison

OTH vs SERA Comparison

Compare OTH & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OTH

Off The Hook YS Inc.

N/A

Current Price

$2.45

Market Cap

67.2M

Sector

Industrials

ML Signal

N/A

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

N/A

Current Price

$2.04

Market Cap

77.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OTH
SERA
Founded
2012
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Precision Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.2M
77.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OTH
SERA
Price
$2.45
$2.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.0K
86.5K
Earning Date
12-15-2025
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.32
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
N/A
$25.84
Revenue Next Year
N/A
$715.79
P/E Ratio
$600.18
N/A
Revenue Growth
N/A
5.19
52 Week Low
$1.95
$1.37
52 Week High
$3.75
$4.17

Technical Indicators

Market Signals
Indicator
OTH
SERA
Relative Strength Index (RSI) 51.13 44.66
Support Level $2.03 $1.80
Resistance Level $2.72 $3.45
Average True Range (ATR) 0.28 0.21
MACD -0.02 0.03
Stochastic Oscillator 66.67 48.15

Price Performance

Historical Comparison
OTH
SERA

About OTH Off The Hook YS Inc.

Off The Hook YS Inc operates as a nationwide leader in the yacht and boat dealership industry, offering a comprehensive suite of services that spans the entire boat value chain. The company operates as two segments: Boat Sales and Azure Funding. Boat Sales includes Specializing in the buying, selling, and wholesaling of yachts and boats, having a boat dealership created to run Yellow Fin sales in Miami; and Azure Funding includes a recreational loan broker and lender providing financing solutions for individuals, dealerships, and brokerages.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: